In contrast to other multi–tyrosine kinase inhibitors, cabozantinib targets VEGFR-1–3 as well as MET and the tumor-associated macrophage (TAM) family (TYRO3, AXL, and MER) of receptor kinases [11,15]. Here, MET is linked to neoplasm.